Liposomal Bupivacaine Versus Non-liposomal Bupivacaine for Total Shoulder Arthroplasty
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to validate the analgesic efficacy of admixed Liposomal
bupivacaine (LB) + bupivacaine compared with plain bupivacaine when injected for interscalene
nerve block (ISNB) for total shoulder arthroplasty (TSA). We hypothesize that admixed LB will
be non-inferior to plain bupivacaine in terms of postoperative opioid consumption following
TSA. The primary outcome of this study will be opioid consumption over the first 72 hours
following surgery. Secondary outcomes will include: pain scores, opioid-related adverse
events, block related adverse events, pain related phone calls, pain related ED visits and
patient satisfaction.